Mont MA, Cherian JJ, Sierra RJ, et al. Nontraumatic osteonecrosis of the femoral head: Where do we stand today? A ten‐year update. J Bone Joint Surg Am. 2015; 97(19):1604–1627.83 83. Chughtai M, Piuzzi NS, Khlopas A, et al. An evidence‐based guide to the treatment of osteonecrosis of the femoral head. Bone Joint J. 2017; 99–b(10):1267–1279.
84 84. Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019; 4(3):85–97.
85 85. Osmani F, Thakkar S, Vigdorchik J. The utility of conservative treatment modalities in the management of osteonecrosis. Bull Hosp Jt Dis. 2017; 75(3):186–192.
86 86. Li D, Yang Z, Wei Z, Kang P. Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA‐compliant meta‐analysis of animal studies and clinical trials. Sci Rep. 2018; 8(1):1450.
87 87. Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of corticosteroid‐related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009; 40(2):235–239.
88 88. Glueck CJ, Freiberg RA, Sieve L, Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005( 435):164–170.
89 89. Hua KC, Yang XG, Feng JT, et al. The efficacy and safety of core decompression for the treatment of femoral head necrosis: a systematic review and meta‐analysis. J Orthop Surg Res. 2019; 14(1):306.
90 90. Sugioka Y, Hotokebuchi T, Tsutsui H. Transtrochanteric anterior rotational osteotomy for idiopathic and steroid‐induced necrosis of the femoral head. Indications and long‐term results. Clin Orthop Relat Res. 1992( 277):111–120.
91 91. Seki T, Hasegawa Y, Masui T, et al. Quality of life following femoral osteotomy and total hip arthroplasty for nontraumatic osteonecrosis of the femoral head. J Orthop Sci. 2008; 13(2):116–121.
92 92. Powell GF, Brasel JA, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. I. Clinical evaluation of the syndrome. N Eng J Med. 1967; 276(23):1271–1278.
93 93. Powell GF, Brasel JA, Raiti S, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinologic evaluation of the syndrome. N Eng J Med. 1967; 276(23):1279–1283.
94 94. Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid‐induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab. 1998; 83(8):2824–2829.
95 95. Tejani A, Butt KM, Rajpoot D, et al. Strategies for optimizing growth in children with kidney transplants. Transplantation. 1989; 47(2):229–233.
96 96. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate‐day corticosteroid treatment after kidney transplantation. J Pediatr. 1992; 120(5):721–725.
97 97. Reimer LG, Morris HG, Ellis EF. Growth of asthmatic children during treatment with alternate‐day steriods. J Allergy Clin Immunol. 1975; 55(4):224–231.
98 98. Ketterl TG, Chow EJ, Leisenring WM, et al. Adipokines, inflammation, and adiposity in hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2018; 24(3):622–626.
99 99. Armenian SH, Chemaitilly W, Chen M, et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: The cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transplant. 2017; 23(2):201–210.
100 100. Kamel A, Norgren S, Elimam A, et al. Effects of growth hormone treatment in obese prepubertal boys. J Clin Endocrinol Metab. 2000; 85(4):1412–1419.
101 101. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years experience. Blood. 2009; 113(2):306–308.
102 102. Vexiau P, Perez‐Castiglioni P, Socié G, et al. The 'euthyroid sick syndrome': incidence, risk factors and prognostic value soon after allogeneic bone marrow transplantation. Br J Haematol. 1993; 85(4):778–782.
103 103. Lee V, Cheng PS, Chik KW, et al. Autoimmune hypothyroidism after unrelated haematopoietic stem cell transplantation in children. J Pediatr Hematol/Oncol. 2006; 28(5):293–295.
104 104. Karthaus M, Gabrysiak T, Brabant G, et al. Immune thyroiditis after transplantation of allogeneic CD34+ selected peripheral blood cells. Bone Marrow Transplant. 1997; 20(8):697–699.
105 105. Patriarca F, Skert C, Sperotto A, et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft‐vs‐host disease and immune recovery. Exp Hematol. 2006; 34(3):389–396.
106 106. Lortan JE, Rochfort NC, el Tumi M, Vellodi A. Autoantibodies after bone marrow transplantation in children with genetic disorders: relation to chronic graft‐versus‐host disease. Bone Marrow Transplant. 1992; 9(5):325–330.
107 107. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003; 361(9372):1881–1893.
108 108. Krasner AS. Glucocorticoid‐induced adrenal insufficiency. J Am Med Assoc. 1999; 282(7):671–676.
109 109. Oelkers W. Adrenal insufficiency (Review). N Eng J Med. 1996; 335(16):1206–1212.
110 110. Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in long‐term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol/Oncol. 2004; 26(2):81–90.
111 111. Jim HS, Sutton SK, Jacobsen PB, et al. Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation. Cancer. 2016; 122(8):1290–1297.
112 112. Baker KS, Leisenring WM, Goodman PJ, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood. 2019; 133(26):2790–2799.
113 113. Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li‐Fraumeni syndrome. Clin Cancer Res. 2017; 23(11):e38–e45.
114 114. Naldi L, Adamoli L, Fraschini D, et al. Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia. Cancer. 1996; 77(7):1402–1408.
115 115. Taitz J, Cohn RJ, White L, et al. Osteochondroma after total body irradiation: an age‐related complication. Pediatr Blood Cancer. 2004; 42(3):225–229.
116 116. Armenian SH, Sun CL, Francisco L, et al. Health behaviors and cancer screening practices in long‐term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant. 2012; 47(2):283–290.
117 117. van de Poll‐Franse LV, Nicolaije KA, Ezendam NP. The impact of cancer survivorship care plans on patient and health care provider outcomes: a current perspective. Acta Oncol. 2017; 56(2):134–138.
118 118. Majhail NS, Murphy E, Laud P, et al. Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. Haematologica. 2019; 104(5):1084–1092.
119 119. Hashmi SK, Lee SJ, Savani BN, et al. ASBMT practice guidelines committee survey on long‐termfollow‐up clinics for hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2018; 24(6):1119–1124.
120 120. Hashmi
